Prevalence of symptoms and risk of XXXX in primary care.

@entity1 @entity101 @entity28 @entity387 @entity27 @entity25
BACKGROUND: To obtain prevalence estimates for key symptoms and features that can indicate the presence of @entity27 ( @entity27 ) in a broad range of primary care settings. DESIGN: Cross-sectional survey. SETTING: Forty offices and clinics in the United States, Germany, and Spain. @entity1 : Consecutive @entity1 who were > 15 years of age, regardless of the reason for the visit. MEASUREMENTS: We collected demographic information, prevalence of self-reported chronic snoring, @entity25 , @entity28 (body mass index [BMI] > 30), @entity101 , and calculation of @entity27 risk, and we also compared results between the United States and Europe. RESULTS: There was a 78% return rate for 8,000 surveys (mean age, 51 years; age range, 15 to 98 years; 52% @entity1 ). One third of @entity1 (32%) had a high pretest probability for @entity27 , with a higher rate in the United States (35.8% of 3,915 @entity1 ) than in Europe (26.3% of 2,308 @entity1 ; p < 0.001; age-matched and sex-adjusted odds ratio [OR], 1.37; 95% confidence interval [CI], 1.16 to 1.61). @entity25 (32.4% vs 11.8%, respectively; p < 0.001) followed by @entity28 and/or @entity101 (44.8% vs 37.1%, respectively; p < 0.01) contributed to the @entity27 risk difference between @entity1 in the United States and Europe, as frequent snoring and breathing pauses were similarly reported (44%). A high pretest probability for @entity27 was more often present in @entity1 than in @entity1 (37.9% vs 27.8%, respectively; p < 0.005; OR, 1.96; CI, 1.59 to 2.88) and in those that were @entity28 (ie, BMI, > or = 30 kg/m(2)), a condition that is generally more common in the US population than in the European population (27.9% vs 17.2%, respectively; p < 0.01). CONCLUSIONS: Primary care physicians in the United States and Europe will encounter a high demand for services to confirm or manage @entity387 , @entity25 , and @entity28 .
